These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 29632007)
41. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203 [TBL] [Abstract][Full Text] [Related]
42. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation. Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746 [TBL] [Abstract][Full Text] [Related]
43. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Evens AM; Choquet S; Kroll-Desrosiers AR; Jagadeesh D; Smith SM; Morschhauser F; Leblond V; Roy R; Barton B; Gordon LI; Gandhi MK; Dierickx D; Schiff D; Habermann TM; Trappe R Am J Transplant; 2013 Jun; 13(6):1512-22. PubMed ID: 23721553 [TBL] [Abstract][Full Text] [Related]
44. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830 [TBL] [Abstract][Full Text] [Related]
45. B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry. Sundin A; Grzywacz BJ; Yohe S; Linden MA; Courville EL Hum Pathol; 2017 Mar; 61():140-147. PubMed ID: 27993575 [TBL] [Abstract][Full Text] [Related]
47. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Tse E; Kwong YL Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733 [TBL] [Abstract][Full Text] [Related]
48. [Primary central nervous system post-transplant lymphoproliferative disorders]. Honda M; Koga M; Kanda T Brain Nerve; 2014 Aug; 66(8):947-54. PubMed ID: 25082316 [TBL] [Abstract][Full Text] [Related]
49. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review. Zhu K; Chen J; Chen S Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722 [TBL] [Abstract][Full Text] [Related]
50. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Kordelas L; Trenschel R; Koldehoff M; Elmaagacli A; Beelen DW Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508 [TBL] [Abstract][Full Text] [Related]
51. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525 [TBL] [Abstract][Full Text] [Related]
52. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894 [TBL] [Abstract][Full Text] [Related]
53. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052 [TBL] [Abstract][Full Text] [Related]
54. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562 [TBL] [Abstract][Full Text] [Related]
55. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791 [TBL] [Abstract][Full Text] [Related]